Dupilumab Use Is Associated With Protection From Coronavirus Disease 2019 Mortality: A Retrospective Analysis
Alexandra N. Donlan, Indika Mallawaarachchi, Jennifer Sasson, Robert Preißner, Johanna Loomba, William A. Petri
Abstract
We previously found that type 2 immunity promotes coronavirus disease 2019 (COVID-19) pathogenesis in a mouse model. To test relevance to human disease, we used electronic health record databases and determined that patients on dupilumab (anti-interleukin [IL]-4R monoclonal antibody that blocks IL-13 and IL-4 signaling) at the time of COVID-19 infection had lower mortality.
Topics & Concepts
MedicineDupilumabCoronavirus disease 2019 (COVID-19)Coronavirus2019-20 coronavirus outbreakRetrospective cohort studyDiseaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BetacoronavirusVirologyImmunologyInfectious disease (medical specialty)Internal medicineOutbreakAsthmaMicroscopic ColitisDermatology and Skin DiseasesAsthma and respiratory diseases